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Abstract
Background: Second-generation antipsychotics are commonly prescribed for pediatric patients with schizophrenia
and schizophrenia spectrum disorders despite their lack of approval for use in children. Although considered a safer
alternative to first-generation antipsychotics, there is evidence to suggest that second-generation antipsychotics
may be associated with some adverse events as well as an increase in prolactin levels. The purpose of this review is
to examine the risk of prolactin-related adverse events in pediatric patients using antipsychotics and to quantify
changes in prolactin for this population.
Methods: Literature searches were conducted in Medline, Embase, the Cochrane Central Register of Controlled
Trials, and PsycINFO databases, supplemented with review of select gray literature to identify both randomized
controlled trials and observational studies on pediatric patients prescribed antipsychotic medications for
schizophrenia or schizophrenia spectrum disorders. Using a narrative approach, data on adverse events were
recorded and changes from baseline in prolactin were pooled, where possible, from the randomized trials. Change
from baseline in prolactin was evaluated for each treatment, as well as in comparison to placebo and to other
treatments. Where data was available, these changes were evaluated separately for male and female patients.
Results: Six randomized controlled trials and five observational studies, all examining the effects of second-generation
antipsychotics, were selected. Literature reporting the effects of risperidone, quetiapine, aripiprazole, olanzapine, and
paliperidone was identified, with varying doses. Prolactin-related adverse events were sparsely reported across studies.
In evidence gathered from randomized controlled trials, risperidone, olanzapine, and two doses of paliperidone
(3–5 mg/day and 6–12 mg/day) were associated with increased prolactin levels compared to baseline. With the
exception of paliperidone, similar trends were observed in males and females, separately. The findings of the
observational evidence served to both complement and run contrary to the randomized trials, with discrepancies
attributed to differences in patient and treatment characteristics.
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Conclusions: No definitive conclusions between second-generation antipsychotic use and prolactin-related
adverse events can be made based on the available literature. While some trends in prolactin level changes
emerged, this was based on few trials with small sample sizes. Future investigations should emphasize
reporting on treatment safety.
Trial registration: PROSPERO CRD42014009506.
Keywords: Schizophrenia, Pediatric, Prolactin, Systematic review
Background
First-generation antipsychotics (FGAs), developed in the
1950s, were the first class of antipsychotics to be
prescribed for schizophrenia. However, FGAs were asso-
ciated with adverse events such as extrapyramidal motor
control disabilities [1]. Second-generation antipsychotics
(SGAs) were developed with the aim of providing similar
or greater efficacy in the reduction of schizophrenia-
related symptoms with a reduction in adverse events.
Of the men and women diagnosed with schizophrenia,
40 % and 23 %, respectively, will be diagnosed before the
age of 19 [2]. While SGAs have not been approved for
use in the Canadian pediatric population [3], they are
nevertheless widely prescribed for these patients [4, 5].
Between 1999 and 2008 antipsychotic use in Canada for
patients aged 18 years or younger increased from 1.9 per
1000 to 7.4 per 1000 [6]. However, while SGAs are con-
sidered a safer alternative to FGAs due to the reduced
tendency to induce adverse neurological effects, other
equally problematic adverse events have been associated
with SGAs, especially in the pediatric population [7].
Hyperprolactinemia may become a clinical concern
when patients are prescribed medications that block the
inhibition of prolactin secretion, such as through inter-
ference with tuberoinfundibular dopamine pathway [8].
In 2011, the Canadian Alliance for Monitoring Effective-
ness and Safety of Antipsychotics in Children published
a report on the association between elevated prolactin
levels and adverse events such as gynecomastia, galactor-
rhea, menstrual irregularities, sexual dysfunction, and de-
creased libido [9]. The effect of prolactin on gynecomastia
in men and galactorrhea in women has also been reported
elsewhere [10].
The effect of antipsychotics to raise prolactin levels have
been summarized in a review by Byerly et al. [11]. Risperi-
done, in particular, has been associated with a greater than
normal elevation in prolactin levels compared to other
SGAs in both pediatric and adult populations [11–15].
Despite lack of approval, there is considerable off-label
use of risperidone in Canadian pediatric patients [16].
The primary objective of this review is to examine the
risk of prolactin-related adverse events associated with the
use of antipsychotic medications for the treatment of
schizophrenia and schizophrenia spectrum disorders in
pediatric patients. The secondary objective is to examine
changes in prolactin levels associated with the use of anti-
psychotic medications in this patient population.
Methods
Search strategy
The systematic review protocol (PROSPERO
CRD42014009506) has been described elsewhere [17].
Briefly, clinical literature databases were systematically
searched to identify randomized controlled trials (RCTs)
and observational studies evaluating changes in prolactin
levels and prolactin-related adverse events in pediatric
patients, aged 5 to 18 years, diagnosed with schizophre-
nia or schizophrenia spectrum disorders and treated
with first- or second-generation antipsychotics. For
studies that included a control group, eligible compara-
tors included first- and second-generation antipsychotics
or placebo. The databases searched include: Medline,
Embase, Cochrane Central Register for Controlled
Trials, PsycINFO, ClinicalTrials.gov, the International
Clinical Trials Registry Platform, and the Drug Industry
Document Archive.
Study selection
Two reviewers, working independently, scanned all
abstracts and relevant material identified in the literature
search. The same two reviewers independently reviewed
relevant abstracts in full-text. Discrepancies between the
studies selected by the two reviewers were resolved by
consensus. When necessary, a third reviewer was
consulted.
Data extraction and quality assessment
Two reviewers working independently extracted data on
study characteristics, interventions, patient characteris-
tics at baseline, and outcomes for the study populations
of interest for the final list of selected eligible studies.
Study characteristics extracted included study design,
inclusion and exclusion criteria, active treatment
duration, and study quality items. Intervention charac-
teristics extracted included dose, frequency of administra-
tion, duration, and concomitant/background therapies.
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Patient baseline characteristics extracted included age,
sex, ethnicity, baseline prolactin levels (for males, females,
and both sexes combined), previous antipsychotic use, age
of schizophrenia onset, years since diagnosis, age at
diagnosis, and schizophrenia subtype. Baseline disease
severity scores from the Positive and Negative Syndrome
Scale (PANSS) and the Brief Psychiatric Rating Scale
(BPRS) were also extracted. Discrepancies between
reviewers were resolved by involving a third reviewer and
coming to a consensus.
For included RCTs, the quality of individual trials was
assessed using the Risk of Bias instrument endorsed by
the Cochrane Collaboration [18]. This instrument is
used to evaluate 7 key domains: sequence generation,
allocation concealment, blinding of participants and
personnel, blinding of outcome assessors, incomplete
outcome data, selective outcome reporting, and other
sources of bias. For included observational studies, the
quality of individual studies was assessed using the
Newcastle-Ottawa Scale (NOS) [19]. This instrument is
used to assess selection of patients, comparability of co-
horts, and adequacy of outcomes and exposures.
Data synthesis and analysis
Data across studies were compared to identify possible
trends between treatments with regards to incidence of
adverse events and changes in prolactin levels from
baseline in a narrative review. RCT and observational
evidence were examined separately. Data for both study
designs were extracted as either binary (prolactin-related
adverse events) or continuous (change in prolactin
levels). Data on change in prolactin levels were extracted
for both males and females separately as well as one ag-
gregate group (males and females together). In the ab-
sence of estimates for mean change form baseline in
prolactin levels, this was calculated where baseline pro-
lactin levels and endpoint prolactin levels were pre-
sented by subtraction of the means (calculation of the
confidence interval by pooling of the standard errors of
the two estimates). Where mean and confidence inter-
vals of change in prolactin levels were provided for two
of the three groups, both mean and standard error
(which was used to calculate the confidence interval)
were back-calculated to obtain estimates for the third
group (for instance, if mean change in prolactin levels
for both males and females aggregated was presented as
well as data on males, this could be used to back-
calculate estimates for females). Pooled proportions were
calculated where multiple studies assessed the same
treatment regimen and were calculated as the back-
transformation of the weighted mean of the transformed
proportions, as outlined by Miller 1978 [20]. Finally,
forest plots were created depicting extracted data
from RCTs (not created for data from observational
studies due to expected heterogeneity in treatment
duration between studies). These depict differences in
mean change from baseline in prolactin levels be-
tween treatments. Forest plots and pooled proportions
summarizing relevant outcome data were created in
StatsDirect (Version 2.8.0).
Results
Of the 15,184 abstracts identified, 1,075 were evaluated
at the full-text level. During the abstract screening
phase, the most common reasons for exclusion were:
studies were systematic reviews (classified as excluded
for study design); studies were duplicates (classified as
excluded for other); and studies assessed a population
over 18 years of age (classified as excluded for popula-
tion). The most common reason for exclusion in the
full-text screening phase was a population over 18 years
of age (classified as excluded for population). Eleven eli-
gible studies were included, consisting of six RCTs and
five non-randomized observational studies. Study flow is
presented in Fig. 1.
Evidence from RCTs
All six included RCTs evaluated the use of SGAs [21–26].
The interventions assessed by these studies include four
dose ranges of risperidone (1–3 mg/day, 4–6 mg/day,
1.5-6 mg/day, and 0.15–0.6 mg/day) [23, 26], two
doses of quetiapine (400 mg/day and 800 mg/day)
[21], two doses of aripiprazole (10 mg/day and 30 mg/day)
[22], olanzapine 2.5–20 mg/day [24], and three doses of
paliperidone (1.5 mg/day, 3–6 mg/day, and 6–12 mg/day)
[25]. All RCTs, with the exception of Haas et al. 2009b,
included a placebo control arm [26]. Characteristics of
included RCTs are presented in Table 1.
Fig. 1 PRISMA study flow diagram
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Treatment duration for most studies was 6 weeks,
with the exception of Haas et al. 2009b which reported
outcomes after an 8 week treatment duration [26]. All
RCTs included adolescent patients, with age at enroll-
ment restrictions varying between 12 and 18 years.
Three RCTs only included patients with a PANSS score
between 60 and 120 [23, 25, 26] while one study
included any patients with a PANSS score of 60 or above
[21] and one study included patients with a PANSS
score of 70 or above [22].
Baseline patient characteristics
Patient baseline characteristics are presented in Table 2.
Baseline characteristics were generally well balanced,
both between treatment arms and trials. Mean age var-
ied between 15.1 and 16.3 years for all included RCTs
and the percentage of males varied between 45 % and
73 %. The distribution of males between study arms dif-
fered significantly for two trials, one reporting on the
effects of aripiprazole, with percentages between 45 %
and 64 % for the three arms [22], and the other report-
ing on paliperidone, with percentages between 45 % and
70 % for the four trial arms [25]. The majority of the
study populations consisted of Caucasians, with all other
races and ethnicities making up less than one quarter of
each study arm in most studies. In the study by Haas et
al. 2009a, however, Asian patients comprised over a
third of the study population.
Of the three RCTs reporting on previous antipsychotic
use, two reported percentages of patients with previous
antipsychotic use above 70 % in all arms [24, 25] and
one reported previous antipsychotic use of 46 %, 53 %,
and 46 % in the placebo arm, aripiprazole 10 mg/day
arm, and aripiprazole 30 mg/day arm, respectively [22].
Three RCTs reported mean age of onset of symptoms
related to schizophrenia, which varied between 12.5 and
14.2 years of age [22, 24, 26]. Three RCTS reported
mean age at diagnosis of schizophrenia, which was also
Table 1 Characteristics of included studies























































































Quetiapine 200–800 mg/day 12 Aged 12–17 years;
PANSS≥ 60
BPRS Brief psychiatric rating scale, DSM Diagnostic and Statistical Manual of Mental Disorders, K-SADS-PL Kiddie Schedule for Affective Disorders and Schizophrenia
for School-Age Children – Present and Lifetime Version, PANSS Positive and negative syndrome scale, TR text revision
aPatients were allocated to three treatment arms as treatment-naïve, treatment-experienced, and open-label treatment. Patients in the treatment-naïve and
treatment-experienced arms were evaluated at 24 weeks and patients in the open-label arm were evaluated at 48 weeks
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Table 2 Summary of baseline characteristics
Study N (ITT) Treatment Age, mean
(SD)























73 Quetiapine 400 mg/day 15.5 (1.3) 43 (58.9) 45 (61.6) 20.8 (17.0) NR NR NR NR 96.2 (17.7)
74 Quetiapine 800 mg/day 15.5 (1.3) 44 (59.5) 44 (59.5) 18.1 (20.1) NR NR NR NR 97.0 (15.3)
73 Placebo 15.3 (1.4) 42 (57.5) 46 (63.0) 28.7 (29.1) NR NR NR NR 96.7 (18.0)
Findling et al.
2008 [22]
100 Aripiprazole 10 mg/day 15.6 (1.3) 45 (45.0) 5]4 (54.0) NR NR NR 53 (53.0) NR 93.7 (15.7)
102 Aripiprazole 30 mg/day 15.4 (1.4) 65 (63.7) 62 (60.8) NR NR NR 47 (46.1) NR 94.9(15.5)
100 Placebo 15.4 (1.4) 61 (61.0) 64 (64.0) NR NR NR 46 (46.0) NR 95.0(15.5)
Haas et al.
2009a [23]
55 Risperidone 1–3 mg/day 15.7 (1.3) 30 (54.5) 33 (60.0) 29.6 (38.2) 21.6 (15.2) 39.2 (53.0) NR 38 (69.1) NR
51 Risperidone 4–6 mg/day 15.7 (1.3) 37 (72.5) 24 (47.1) 24.1 (23.0) 22.7 (19.9) 27.9 (28.3) NR 34 (66.7) NR
54 Placebo 15.5 (1.4) 35 (64.8) 27 (50.0) 22.6 (23.3) 21.5 (21.1) 24.6 (25.9) NR 38 (70.4) NR
Haas et al.
2009b [26]
125 Risperidone 1.5–6 mg/day 15.6 (1.3) 65 (52.0) 104 (83.2) NR NR NR NR 83 (66.4) 96.4 (15.4)
132 Risperidone 0.15–0.6 mg/day 15.6 (1.3) 80 (60.6) 111 (84.9) NR NR NR NR 92 (69.7) 93.3 (14.1)
Kryzhanovskaya et al.
2009 [24]
72 Olanzapine 2.5–20 mg/day 16.1 (1.3) 51 (70.8) 52 (72.2) 15.6 (12.3) NR NR 51 (70.8) NR 95.3 (14.1)
35 Placebo 16.3 (1.6) 24 (68.6) 25 (71.4) 18.7 (16.2) NR NR 30 (85.7) NR 95.5 (14.1)
Singh et al.
2011 [25]
54 Paliperidone 1.5 mg/day 15.1 (1.5) 30 (55.6) 35 (64.8) 25.1 (32.8) 14.7 (14.5) 38.0 (45.5) 47 (87.0) NR 91.6 (12.5)
48 Paliperidone 3–6 mg/day 15.3 (1.6) 31 (64.6) 34 (70.8) 26.6 (43.2) 16.1 (1.8) 45.67 (71.0) 44 (91.7) NR 90.6 (14.0)
47 Paliperidone 6–12 mg/day 15.5 (1.6) 33 (70.2) 32 (68.1) 20.8 (22.3) 18.2 (13.7) 26.88 (33.9) 40 (85.1) NR 91.5 (13.9)




16 Risperidone 1–6 mg/day 15.7 (1.3) 10 (62.5) 16 (100.0) 16 (9) NR NR NR NR NR
Kumra et al.
2008 [28]
14 Clozapine 25–900 mg/day 15.3 (2.3) 5 (35.7) 1 (7.1) NR NR NR 14 (100.0) NR NR
19 Olanzapine 30 mg/day 15.6 (1.7) 11 (57.9) 5 (26.3) NR NR NR 19 (100.0) NR NR
Pandina et al.
2012 [29]
48 Risperidone 2–6 mg/day
(treatment-naïve)
15.4 (1.4) 30 (62.5) 25 (52.1) 17.0 (20.4) 18.6 (24.7) 14.3 (6.7) NR 33 (68.8) 84.7 (16.8)
292 Risperidone 2–6 mg/day
(treatment-experienced)
15.5 (1.7) 178 (61.0) 218 (74.7) 53.4 (33.9) 40.4 (26.3) 73.6 (43.0) 292 (100.0) 195 (66.8) 72.1 (19.4)
50 Risperidone 2–6 mg/day
(open-label)
15.5 (1.4) 30 (60.0) 42 (84.0) 73.6 (44.9) 55.8 (25.3) 100.3 (62.3) NR 35 (70.0) 83.9 (13.5)
Ruan et al.
2010 [30]
31 Risperidone 25–50 mg
biweekly
15.9 (3.3) 13 (41.9) NR 54.8 (17.7) NR NR NR 24 (77.4) 57.8 (1.8)
Schimmelmann et al.
2007 [31]
56 Quetiapine 200–800 mg/day 15.9 (1.3) 38 (67.9) 47 (83.9) 15.9 (23.3) 12.6 (6.3) 22.9 (41.4) 13 (23.2) NR 91.5 (17.2)












similar across trials, varying from 12.5 years of age to
15.3 years of age [23, 25, 26]. In addition, two three-arm
studies reported mean years since schizophrenia diagnosis,
which was similar in all three arms for both studies [21,
22]. Three RCTs reported the proportion of patients diag-
nosed under each schizophrenia subtype [21, 23, 26]. In
all of these studies, the majority of patients were diag-
nosed with paranoid schizophrenia, followed by undiffer-
entiated schizophrenia and disorganized schizophrenia
[23, 26]. No study reported age at first psychosis.
Baseline disease severity assessments were consist-
ent across studies. Most RCTs reported baseline
disease severity using the PANSS, with mean values
varying from 90.6 to 97.0 [21, 22, 24–26]. One RCT
reported mean baseline BPRS scores of 50.3 and 50.1
for the olanzapine 2.5–20 mg/day and placebo arms,
respectively [24].
Two studies reported overall population baseline prolac-
tin levels, with Findling et al. (2012) reporting mean base-
line values between 18.1 ng/mL and 28.7 ng/mL and
Kryzhanovskaya et al. (2009) reporting mean baseline
values between 15.6 ng/mL and 18.7 ng/mL [21, 24]. Add-
itionally, two trials reported baseline prolactin levels for
both males and females separately. For males, Haas et al.
(2009a) reported mean baseline values from 21.5 ng/mL
and 22.7 ng/mL, while Singh et al. (2011) reported values
between 13.6 ng/mL and 18.2 ng/mL [23, 25]. Baseline
prolactin levels were higher in females, but similar across
studies, as Haas et al. (2009a) reported values between
24.6 ng/mL and 39.2 ng/mL, while Singh et al. (2011) re-
ported values between 26.9 ng/mL and 45.7 ng/mL [23, 25].
Overall population baseline prolactin levels were calculated
for these two studies.
Outcomes
Prolactin-related adverse events Prolactin-related ad-
verse events were sparsely reported (see Table 3). Three
RCTs reported overall prolactin-related adverse events,
gynecomastia/galactorrhea, and amenorrhea/dysmenor-
rhea in patients treated with varying doses of aripipra-
zole and risperidone [22, 23, 26]. In two studies, which
assessed aripiprazole and risperidone, no cases of
prolactin-related adverse events were reported [22, 23].
A study comparing doses of risperidone of 1.5–6 mg/day
and 0.15–0.6 mg/day reported seven events (5.6 % of
study patients) and two events (1.5 %), respectively [26].
Specifically, investigators reported three (2.4 %) and two
(1.5 %) cases of gynecomastia/galactorrhea in the risperi-
done 1.5–6 mg/day and risperidone 0.15–0.6 mg/day
arms, respectively, as well as a single case (1.7 % of
female patients) of amenorrhea/dysmenorrhea in the
risperidone 1.5–6 mg/day arm.
Change in prolactin levels: Change from baseline,
treatment-placebo comparison Five RCTs provided
data for mean change in prolactin levels for the overall
population (see Table 4) [21–25]. Mean changes from
baseline compared to placebo for each intervention in
the overall population are presented in Fig. 2.
Compared to baseline, both doses of quetiapine and
aripiprazole resulted in decreased prolactin levels. When
compared to placebo, these changes were significantly
greater compared to baseline for quetiapine but not for
aripiprazole.
Both doses of risperidone, olanzapine, and paliperidone
3–5 mg/day and 6–12 mg/day were found to increase pro-
lactin levels from baseline. These changes also reflected
statistically significant increases when compared to
placebo. Paliperidone 1.5 mg/day was not associated with
a statistically significant change.
Three RCTs reported changes in serum prolactin
levels stratified by sex [21, 23, 25]. When evaluating the
change from baseline for each of the included SGAs,
trends reflected those observed in the overall popula-
tions for both males and females. However, the change
from baseline for females treated with any dose range of
risperidone was higher than males treated with the same
dose. Figures 3 and 4 present the mean changes from
baseline compared to placebo for males and females,
respectively. Compared to placebo, the change from
baseline for females treated with either dose of
quetiapine resulted in a statistically significant differ-
ence. This change was not found to be significant in
males. Compared to placebo, both males and females
were found to experience significant increases when
treated with risperidone, though this increase was
more marked in female patients treated with risperi-
done 4–6 mg/day. Conversely, the change from base-
line compared to placebo was significant for males,
but not females, treated with paliperidone 3–6 mg/day
and 6–12 mg/day.
Change in prolactin levels: Change from baseline,
treatment-treatment comparison Figure 2 presents
comparisons for change from baseline in prolactin levels
between treatments for the overall population. Risperidone
4–6 mg/day reported a greater increase in prolactin levels
when compared with the lower dose of 1–3 mg/day. Simi-
larly, both paliperidone 3–6 mg/day and 6–12 mg/day
reported a greater increase in prolactin levels when com-
pared with paliperidone 1.5 mg/day. However, the differ-
ence between paliperidone 6–12 mg/day and 3–6 mg/day
was not statistically significant. Further, no statistically
significant differences were reported for the comparisons
between quetiapine 400 mg/day and 800 mg/day or
between aripiprazole 30 mg/day and 10 mg/day.
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Figures 3 and 4 present comparisons of change in pro-
lactin levels from baseline between treatments for the
male and female populations, respectively. The compari-
son between risperidone at 4–6 mg/day and 1–3 mg/day
was significant in the female population, but not in the
male population, with the higher dose producing a greater
change from baseline for both populations. Similarly,
comparisons between quetiapine 800 mg/day and
400 mg/day, paliperidone 6–12 mg/day and 1.5 mg/day,
and paliperidone 6–12 mg/day and 1.5 mg/day were sta-
tistically significant in the male population, but not in the
female population, with greater increases observed in the
treatments with the higher dose. The comparison between
paliperidone 6–12 mg/day and paliperidone 3–6 mg/day
was not significant for either patient population.
Evidence from non-randomized, observational studies
Five observational studies were identified which assessed
patient experiences with SGAs [27–31]. The interven-
tions represented in this set of literature included three
doses of risperidone (1–6 mg/day, 2–6 mg/day, 25–50 mg
biweekly) [27, 29, 30], quetiapine 200–800 mg/day [31],
clozapine 25–900 mg/day [28], and olanzapine 30 mg/day
[28]. Characteristics of included observational studies are
presented in Table 1.
Table 3 Prolactin-related adverse events















73 Quetiapine 400 mg/day NR NR NR NR
74 Quetiapine 800 mg/day NR NR NR NR
73 Placebo NR NR NR NR
Findling et al.
2008 [22]
100 Aripiprazole 10 mg/day 0 (0.0) NR NR NR
102 Aripiprazole 30 mg/day 0 (0.0) NR NR NR
100 Placebo 0 (0.0) NR NR NR
Haas et al.
2009a [23]
55 Risperidone 1–3 mg/day 0 (0.0) NR NR NR
51 Risperidone 4–6 mg/day 0 (0.0) NR NR NR
54 Placebo 0 (0.0) NR NR NR
Haas et al.
2009b [26]
125 Risperidone 1.5–6 mg/day 7 (5.6) 3 (2.4) 1 (1.0) NR
132 Risperidone 0.15–0.6 mg/day 2 (1.5) 2 (1.5) 0 (0.0) NR
Kryzhanovskaya et al.
2009 [24]
72 Olanzapine 2.5–20 mg/day NR NR NR NR
35 Placebo NR NR NR NR
Singh et al.
2011 [25]
54 Paliperidone 1.5 mg/day NR NR NR NR
48 Paliperidone 3–6 mg/day NR NR NR NR
47 Paliperidone 6–12 mg/day NR NR NR NR




16 Risperidone 1–6 mg/day NR NR NR NR
Kumra et al.
2008 [28]
14 Clozapine 25–900 mg/day NR NR NR NR
19 Olanzapine 30 mg/day NR NR NR NR
Pandina et al.
2012a [29]
48 Risperidone 2–6 mg/day (treatment-naïve) 36 (9.3) 14 (3.6) 3 (1.0) 1 (<0.5)
292 Risperidone 2–6 mg/day (treatment-
experienced)
50 Risperidone 2–6 mg/day (open-label)
Ruan et al.
2010 [30]
31 Risperidone 25–50 mg biweekly 5 (16.1) 2 (6.5) 3 (9.7) NR
Schimmelmann et al.
2007 [31]
56 Quetiapine 200–800 mg/day NR 3 (5.4) 4 (7.1) 9 (16.1)
ITT Intent to treat, NR Not reported
aIncidence of adverse events reported across all treatment arms
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Two of the observational studies restricted enrollment
to patients with a diagnosis of only schizophrenia [29, 30].
The remaining studies represented patients with schizo-
phrenia, schizoaffective disorder, and schizophreniform
disorder [27, 28, 31]. Three of the observational studies
also specified disease severity in the inclusion criteria, with
PANSS scores restricted to between 40 and 120 [29], 80
or below [30], and 60 or above [31].
Treatment durations varied widely, with one observa-
tional study reporting on patient outcomes after 3 weeks
of treatment [27], two studies after 12 weeks [28, 31],
one study after 24 weeks [30], and one three-arm study
after 24 weeks for two arms and 48 weeks for the third
arm [29]. All observational studies included adolescent
patients with ages varying between 10 and 18 years.
One study, published by Pandina and colleagues
(2012), adopted a non-conventional comparative obser-
vational study methodology [29]. This three-arm study
was designed to include one arm with 24 weeks prior
treatment experience with risperidone 2–6 mg/day
(treatment-experienced arm), one arm with no risperi-
done experience (treatment-naïve arm), and one arm
Table 4 Changes from baseline in prolactin
Study Treatment Time point,
weeks
Prolactin change, both








Quetiapine 400 mg/day 6 −10.6 (16.1) −9.22 (14.4) −12.4 (18.5)
Quetiapine 800 mg/day 6 −7.8 (26.5) −3.7 (11.6) −14.0 (39.1)
Placebo 6 −18.3 (28.8) −6.53 (15.1) −33.9 (34.9)
Findling et al.
2008 [22]
Aripiprazole 10 mg/day 6 −11.9 (23.3) NR NR
Aripiprazole 30 mg/day 6 −15.1 (26.9) NR NR
Placebo 6 −8.5 (24.2) NR NR
Haas et al.
2009a [23]
Risperidone 1–3 mg/day 6 25.5 (33.5) 16 (23.7) 36.9 (41.3)
Risperidone 4–6 mg/day 6 49.5 (46.9) 26.4 (28.5) 77.3 (60.8)
Placebo 6 −5.9 (24.9) −3.2 (24.8) −9.2 (24.1)
Haas et al.
2009b [26]
Risperidone 1.5–6 mg/day 8 NR NR NR
Risperidone 0.15–0.6 mg/day 8 NR NR NR
Kryzhanovskaya et al.
2009 [24]
Olanzapine 2.5–20 mg/day 6 8.8 (17.9) NR NR
Placebo 6 −3.3 (14.8) NR NR
Singh et al.
2011 [25]
Paliperidone 1.5 mg/day 6 3.3 (36.0) 3.6 (19.1) 2.9 (48.6)
Paliperidone 3–6 mg/day 6 22.7 (34.1) 22.8 (30.1) 22.4 (38.7)
Paliperidone 6–12 mg/day 6 22.4 (35.5) 21.3 (31.1) 24.9 (42.0)




Risperidone 1–6 mg/day 3 47.9 (23.6) NR NR
Kumra et al.
2008 [28]
Clozapine 25–900 mg/day 12 NR NR NR
Olanzapine 30 mg/day 12 NR NR NR
Clozapine 25–900 mg/day 24 NR NR NR





24 66.8 (41.8) 29.1 (32.6) 83.4 (44.7)
Risperidone 2–6 mg/day
(treatment-experienced)
24 −11.6 (43.3) −6.2 (22.2) −14.0 (49.3)
Risperidone 2–6 mg/day
(open-label)
48 6.8 (35.2) 3.7 (28.5) 11.5 (43.3)
Ruan et al.
2010 [30]
Risperidone 25–50 mg biweekly 24 −13.1 (17.1) NR NR
Schimmelmann et al.
2007 [31]
Quetiapine 200–800 mg/day 12 −1.4 (21.1) −4.5 (5.7) 3.2 (21.7)
NR Not reported, SD Standard deviation
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with varying levels of treatment experience prior to
study treatment (open-label arm). At enrollment,
patients received 24 weeks open-label treatment with
risperidone 2–6 mg/day, thus resulting in one arm with
48 weeks of treatment experience and two arms with
24 weeks of treatment experience.
Baseline patient characteristics
Patient baseline characteristics are presented in Table 2.
Mean ages were homogenous across studies, varying be-
tween 15.3 and 15.9 years. However, the distribution of
males and females varied between trials, with percent-
ages of males in each study arm ranging from 36 % to
68 %. Race was reported in four observational studies
[27–29, 31]. In two cases, patient populations were com-
prised either primarily or entirely of Caucasians [27, 31].
Imbalances were reported in the three-arm study, with
the percentage of Caucasian patients ranging from 52 %
to 84 % across arms [29]. The study by Kumra et al.
(2008) comprised a mixed race population with African-
Americans representing the largest percentage of
patients at 36 % and 47 % across treatment arms [28].
Where reported, previous antipsychotic treatment
experience varied from 100 % of patients [28, 29] to less
than 25 % [31]. Similarly, disease severity was not con-
sistent across the included studies. As assessed by the
PANSS, mean reported scores varied from 57.8 to 91.5.
A single study reported mean age of schizophrenia
symptoms of 12.7 and 11.7 for the two treatment arms
[32]. Mean age of diagnosis of schizophrenia or schizo-
phrenia spectrum disorder was reported in a single
study, with ages varying between 14.8 and 15.1 across
study arms [29]. Two observational studies reported
schizophrenia subtype and in both cases the majority of
patients were diagnosed with paranoid schizophrenia
[29, 30]. Overall mean baseline prolactin levels varied
between studies from a minimum of 15.9 ng/mL to a
maximum of 73.6 ng/mL. In two observational studies,
Fig. 2 Forest plot of mean change from baseline for SGAs presented in RCTs, overall population
Fig. 3 Forest plot of mean change from baseline for SGAs presented in RCTs, male population only
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baseline prolactin levels for males and females were
available separately and differed between sexes [29, 31].
Pandina et al. (2012) reported baseline prolactin levels
for males of 18.6 ng/mL, 40.4 ng/mL, and 55.8 ng/mL
and baseline prolactin levels for females of 14.3 ng/mL,
73.6 ng/mL, and 100.3 ng/mL for the treatment-naïve,
treatment-experienced, and open-label arms, respectively
[29]. This difference was not as marked, but still differ-
ent, in the paper by Schimmelmann and colleagues
(2007), which reported levels of 12.6 ng/mL and
22.9 ng/mL for males and females, respectively [31].
Outcomes
Outcomes were typically reported after 12 or 24 weeks
of treatment. Prolactin-related adverse events were re-
ported in three studies; two reporting on patient experi-
ence with varying levels of risperidone [29, 30] and one
with quetiapine 200–800 mg daily [31]. Pandina et al.
(2012) reported 36 (9 %) prolactin-related adverse
events, 14 cases (3.6 %) of gynecomastia/galactorrhea, 3
cases (1.0 %) of amenorrhea/dysmenorrhea, and a single
case (<0.5 %) of impotence or decreased libido across
study arms. These adverse events were not reported by
treatment arm, which differed with regards to prior
treatment experience and treatment duration. In a study
of patients treated biweekly with 25–50 mg of risperi-
done for 24 weeks, 5 cases (16 %) of prolactin-related
adverse events, comprising 2 cases (6.5 %) of
gynecomastia/galactorrhea and 3 cases (9.7 %) of amen-
orrhea/dysmenorrhea, were reported [30]. A single study
assessing quetiapine reported 3 cases (5.4 %) of
gynecomastia/galactorrhea, 4 cases (7.1 %) of amenor-
rhea/dysmenorrhea, and 9 cases (16.1 %) of impotence
or decreased libido [31].
Mean change from baseline in prolactin levels is pre-
sented in Table 4. Mean changes were available in four
studies; one reporting on quetiapine [31] and three
on risperidone [27, 29, 30]. Patients treated with que-
tiapine 200–800 mg/day experienced a mean decrease
of 1.4 ng/mL (standard deviation [SD] 21.1) [31].
Changes in patients treated with risperidone varied
considerably, from a mean increase of 66.8 ng/mL
(SD 41.8) to a mean decrease of 13.1 ng/mL (SD 17.1).
Change from baseline stratified by sex was available in
two studies [29, 31]. In the first study, male patients treated
with quetiapine 200–800 mg/day were found to have a
mean decrease of 4.5 ng/mL (SD 5.7), while females experi-
enced an increase of 3.2 ng/mL (SD 21.7) [31]. In the sec-
ond study, male patients treated with risperidone 2–6 mg/
day who were previously treatment-naïve were found to
have a mean increase of 29.1 ng/mL (SD 32.6), whereas
treatment-experienced patients were found to decrease
levels by 6.2 ng/mL (SD 22.2). Female patients experienced
larger changes from baseline, with treatment-naïve patients
reporting mean increases of 83.4 ng/mL (SD 44.7) and
treatment-experienced patients reporting a mean decrease
of 14.0 ng/mL (49.3). In the open-label arm of this risperi-
done study, which consisted of patients with varying levels
of treatment experience, males were reported to have a
mean increase of 3.7 ng/mL (SD 28.5) while females
reported a mean increase of 11.5 ng/mL (SD 43.3) [29].
Risk of bias assessment
The Cochrane risk of bias tool was used to assess the
quality of included RCTs [18]. A lack of reporting on
sequence generation [21–24] and allocation concealment
[22–24, 26], as well as a lack of completeness for
primary outcome data [22] were raised as causes for
concern in a number of trials. Other sources of bias,
which included lack of reporting on specific baseline
characteristics (prolactin levels) and prior treatment ex-
perience, were deemed high in three studies [22–24].
Overall, included RCTs were deemed to have a minimal
risk of bias. Results of this evaluation are available in the
Additional file 1: Figure S1 and Additional file 2: Table S1.
Fig. 4 Forest plot of mean change from baseline for SGAs presented in RCTs, female population only
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The NOS was used to assess the quality of included
observational studies [19]. All studies, with the exception
of Ruan et al. 2010, studied populations of patients whose
outcomes may be generalized to all pediatric patients with
schizophrenia being treated with antipsychotics. Ruan et
al. 2010 combined two study populations, one previously
treated with olanzapine and the other previously treated
with oral risperidone. However, baseline prolactin
levels in these two groups were differed greatly
(31.3 ng/mL [SD 11.3] and 87.4 ng/mL [SD 15.5] for
patients with previous olanzapine and risperidone
experience, respectively). As prolactin levels are mea-
sured biochemically, ascertainment of exposure pre-
sents minimal risk of bias. The included observational
studies were considered comparable in that diagnoses
and patient ages included were similar. However,
differences in exclusion criteria for baseline disease
severity and study durations did not allow for robust
comparisons (one study had a follow-up time of less
than four weeks, shorter than any of the included
RCTs [27]). In all studies, loss-to-follow up was
accounted for. Overall, this observational evidence
presents a medium to high risk of bias.
Discussion
This review was designed to evaluate the frequency of
prolactin-related adverse events and to consolidate/
quantify differences in prolactin level changes between
antipsychotics in pediatric patients with schizophrenia
and schizophrenia spectrum disorders. No definitive
conclusions can be drawn regarding differences in
prolactin-related adverse events between antipsychotics
due to the paucity of data. However, analyses of mean
change from baseline in prolactin levels demonstrated
some differences between treatments.
A review of the evidence reported in RCTs found
that, in analyses of both the overall population and
the population stratified by patient sex, risperidone at
1–3 mg/day and 4–6 mg/day was associated with an
increase in prolactin levels compared to baseline. This
change was particularly marked in females. When
compared to placebo, both doses of risperidone pro-
duced greater increases in prolactin levels. Risperi-
done 4–6 mg/day was found to produce greater
increases than risperidone 1–3 mg/day in the overall
population. However, this trend was not observed in
males. A single-arm observational study by Duval et
al. reported outcomes in patients treated with risperi-
done 1–6 mg/day. They found that prolactin levels
increased, on average, in these patients after three
weeks of treatment. This finding is in line with the
findings in the RCT evidence. A three-arm study by
Pandina et al. in patients treated with risperidone 2–
6 mg/day reported outcomes at 24 weeks for two
arms, one treatment-naïve and the other treatment-
experienced, and 48 weeks for the remaining open-
label arm. Patients in the treatment-experienced and
open-label arms showed relatively little change in
prolactin levels. However, this may be attributed to
previous treatment experience. Patients in the treatment-
naïve arm experienced increases in prolactin levels, with a
more marked increase in females. However, these changes
were accompanied by large dispersions. The findings in
the treatment-naïve patients reflect those of the RCT evi-
dence that risperidone is associated with an overall in-
crease in prolactin levels. Differences in patient
characteristics such as treatment-experience, which was
not reported in the included RCTs, and time horizons
may explain the contradictory nature between the obser-
vational and RCT evidence.
Paliperidone at doses of 3–6 mg/day and 6–12 mg/day,
but not 1.5 mg/day, was associated with increases in pro-
lactin levels between baseline and endpoint and when
compared to placebo. When evaluating the evidence
stratified by patient sex, the same trend was observed in
males but not in females. Comparisons in the overall
population between paliperidone doses suggest that pali-
peridone 3–6 mg/day and 6–12 mg/day both increase
prolactin more than the 1.5 mg/day dose. However, this
trend only held for males when results were stratified by
patient sex. The difference in change in prolactin between
paliperidone 6–12 mg/day and 3–6 mg/day was not statis-
tically significant. No observational study was identified
reporting on patients treated with paliperidone.
Changes in prolactin levels were significant for both
doses of quetiapine and for aripiprazole in the RCT evi-
dence, with mean decreases compared to baseline. When
compared to placebo, quetiapine 800 mg/day reported
an increase from baseline in prolactin levels over the
study period. This change was statistically significant for
females, but not for males. In the single observational
study reporting on changes in patients treated with
quetiapine, a decrease in prolactin levels in the overall
and male only populations was reported, with a reported
increase for the female population. It is of note that the
dispersions reported with these values were wide. How-
ever, direct comparisons across these bodies of evidence
must be made with caution, given that there a num-
ber of factors that may contribute in explaining the
disparity of these results. For example, the doses
included in the observational study varied consider-
ably, from 200 mg/day to 800 mg/day, while patients
in the RCT were treated with doses of 400 mg/day
and 800 mg/day. Moreover, the observational study
reported outcomes at 12 weeks, while the RCT
reported outcomes at 6 weeks.
The findings of this review are generally in agreement
with recent reviews on changes in prolactin levels
Druyts et al. BMC Pediatrics  (2016) 16:181 Page 11 of 14
relating to the use of antipsychotic medications [33, 34].
A 2012 review by Cohen et al. reported on short-term (3
to 12 week) outcomes from SGA use in child and ado-
lescent patients for the management of a number of
diagnoses, including schizophrenia, bipolar disorder, and
conduct disorder. They identified four studies on the use
of aripiprazole where patients were reported to have sta-
tistically significant decreases in prolactin levels com-
pared to baseline. This is consistent with the findings of
the current review. However, when changes from base-
line were compared between aripiprazole and placebo in
the current review, this decrease was not found to be
statistically significant. Compared to placebo, Cohen re-
ported that risperidone and olanzapine both produced
increases in prolactin levels, which is consistent with the
findings of the current review. Similarly, Leucht et al. re-
ported increases in prolactin levels associated with the
use of risperidone and paliperidone. However, the dose
of paliperidone was not specified. In the current review,
paliperidone was found to increase prolactin levels at the
3–6 mg/day and 6–12 mg/day dose ranges, but not in
patients treated with the 1.5 mg/day regimen. Consistent
with the current review, treatment with aripiprazole was
not found to increase prolactin compared to placebo.
Leucht et al. also found that quetiapine was not associated
with increases when compared to placebo. In the current
review, however, treatment with quetiapine at both the
400 mg/day and 800 mg/day doses was found to increase
prolactin levels relative to placebo in the overall popula-
tion. Treatment with olanzapine was found, by Leucht et
al., to increase prolactin relative to placebo, which is con-
sistent with the current review. While the review by
Leucht et al. was also in patients with schizophrenia, the
scope was not limited to children. This difference may
explain discrepancies between findings.
Differences between male and female patients with
respect to the prolactin elevation response, particularly
the more pronounced responses among female patients,
have been described in the literature. A 1992 study of
schizophrenia patients found that serum prolactin in-
creased more markedly in female patients following the
commencement of neuroleptic medications, despite the
female patients receiving lower doses of treatment [35].
Interestingly, the individual patient variability in re-
sponse was also higher in females than males. These
findings supported an earlier study also conducted in
patients with schizophrenia [36]. Similar trends were
observed in the current review, with females having a
higher prolactin elevation response compared to males
when treated with risperidone and quetiapine. However,
an opposite trend was observed for patients treated with
paliperidone 3–6 mg/day or 6–12 mg/day.
Typically, reference ranges for biochemical markers are
established to inform physicians on levels at which these
markers may pose a risk to patient safety. While the endo-
crinology literature documents the effect of prolactin on
the body, no acceptable ranges have been established for
serum prolactin levels in the pediatric population. A 1973
study of 19 normal children aged 2–12 years and 54 ado-
lescent children aged 13–16 years estimated mean prolac-
tin levels in both male and females to be approximately
5 ng/mL [37]. However, patient characteristics were poorly
described, so generalizations must be made with caution.
A study by Cook et al. proposed reference ranges (2.5 to
97.5 percentiles) for pediatric prolactin based on a hospital
sample [38]. Based on this patient sample, the normal
ranges for males and females aged 13 to 15 years of age
were defined as 1.6–16.6 ng/mL and 3.0–14.4 ng/mL, re-
spectively. However, the level of elevation in prolactin
levels that warrants concern for adverse events in children
has yet to be defined. According to some clinical investi-
gators, however, prolactin levels between 18 ng/mL and
30 ng/mL are rarely associated with adverse events related
to the hypothalamic-pituitary-gonadal axis, though pro-
longed elevations nearing 100 ng/mL necessitate clinical
investigation [13]. It is, therefore, difficult to determine
what prolactin levels substantially increase the risk of
prolactin-related adverse events in these patients [39].
Therefore, although some trends emerged in the ana-
lysis of prolactin changes in patients treated with
second-generation antipsychotics, the lack of causal
association precludes conclusions being drawn be-
tween the use of any particular antipsychotic and
prolactin-related adverse events.
This review is useful in that the process and design
was well structured, with screening and data extraction
conducted using a duplicate, consensus-based approach.
Additionally, the body of evidence considered was broad,
including both RCTs and observational studies. While
observational studies may lack the methodological rigor
of RCTs, they may still be considered an important
source of information on treatment efficacy and safety.
Despite this, this review presents some limitations. First,
few trials were identified from the available literature
and many were characterized by small sample sizes. Sec-
ondly, the observational studies suffered from significant
heterogeneity in study populations, both in comparison
to one another and to the RCT evidence base. Similarly,
the patients represented in the evidence base were pri-
marily Caucasians, which may limit the generalizability
of the findings to the wider patient population. Follow-
up time, prior treatment experience, and patient diagno-
ses also differed significantly in the observational studies.
Thirdly, estimates of dispersion were large in each of the
RCTs. Finally, while the mechanism is clear between
prolactin and breast development/lactation, there is no
conclusive research to confirm this association epidemi-
ologically. In a similar vein, it was not possible, from the
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included studies, to directly associate changes in prolac-
tin levels with patient adverse events. While this review
was focused on pediatric patients with schizophrenia, in
order to present outcomes for a well-defined clinical
area, it must also be recognized that the potential for
treatment-related prolactin elevation is not limited to
this population. The risk and effects of prolactin eleva-
tion are an important clinical concern in other diagnos-
tic areas and should be explored.
Conclusion
In summary, while some trends in prolactin level
changes from baseline emerged in the data, no definitive
conclusions on the association between particular
antipsychotic use and prolactin-related adverse events
can be drawn. Nevertheless, clinician monitoring of
prolactin-related adverse events is pertinent. Future
trials examining the effects of antipsychotic medications
for pediatric schizophrenia and schizophrenia spectrum
disorder patients should emphasize reporting on safety
outcomes, with studies of adequate duration to allow for
the observation of these outcomes. Routine monitoring
of serum prolactin levels in study participants is encour-
aged, as this may allow investigators to directly attribute
adverse events to changes in prolactin.
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